Victrelis
boceprevir
boceprevir
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Victrelis is and what it is used for
What you need to know before you take Victrelis
How to take Victrelis
Possible side effects
How to store Victrelis
Contents of the pack and other information
Medicinal product no longer authorised
Victrelis contains the active ingredient boceprevir which helps to fight against hepatitis C infection by stopping the virus multiplying. Victrelis must always be used together with two other medicines. These are called peginterferon alfa and ribavirin. Victrelis must not be used by itself.
Victrelis, in combination with peginterferon alfa and ribavirin, is used for chronic hepatitis C virus infection in adults (also called HCV infection).
Victrelis may be used in adults who are previously untreated for HCV infection or who have previously used medicines called ‘interferons’ and ‘pegylated interferons’.
Victrelis inhibits the direct replication of the virus and contributes in this way to lowering the amount of hepatitis C virus in your body.
are allergic to boceprevir or any of the other ingredients of this medicine (listed in section 6)
are pregnant
have a condition called ‘autoimmune hepatitis’
are taking bepridil, pimozide, lurasidone, oral midazolam, oral triazolam, simvastatin, lovastatin, alfuzosin, silodosin, 'ergot’ type medicines (such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine), lumefantrine, halofantrine, quetiapine, or tyrosine kinase inhibitors.
Do not take Victrelis if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Victrelis.
Reminder: Please also read the “Do not use” section of the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Talk to your doctor or pharmacist before taking your medicine if you:
have ever had a blood problem such as anaemia (when you lack enough healthy red blood cells, which transport oxygen around your body)
have ever had a blood problem such as neutropenia (lack of a certain type of white blood cells).
Neutropenia affects the body's ability to fight off infections
have ever had a blood problem such as pancytopenia (a combination of low platelet, red and white blood cell counts)
have a current or previous infection with the hepatitis B virus, since your doctor may want to monitor you more closely
have liver failure
have another liver problem in addition to hepatitis C infection
have HIV (human immunodeficiency virus) or have ever had any other problems with your immune system
were an organ transplant recipient
have hepatitis C other than genotype 1
were a patient who has previously failed treatment with an HCV protease inhibitor
have or anyone in your family has an irregular heartbeat, especially a condition called “QT prolongation”
Medicinal product no longer authorised
have low blood potassium (hypokalaemia)
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Victrelis.
While taking the combination of Victrelis with ribavirin and peginterferon alpha, serious allergic reactions have been reported. Please see "Possible side effects" for more information.
Your doctor will have your blood tested regularly. These blood tests are done for a number of reasons:
so your doctor knows if the treatment is working for you
to help your doctor decide how long you will be treated with Victrelis.
to check for side effects.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription and herbal medicines.
In particular, do not take Victrelis if you are taking any of the following medicines:
alfuzosin and silodosin – used to treat symptoms of an enlarged prostate
bepridil – used for heart problems
pimozide or lurasidone – used for mental health problems
oral midazolam or oral triazolam – a sedative, given by mouth
statins – simvastatin or lovastatin
‘ergot’ type medicines, such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine – used for migraine and cluster headaches
lumefantrine and halofantrine – anti-malaria medicines
quetiapine - used to treat schizophrenia, bipolar disorder and major depressive disorder
tyrosine kinase inhibitors – used as anti-cancer medicines
Do not take Victrelis if you are taking any of the medicines above. If you are not sure, talk to your doctor or pharmacist before taking Victrelis.
Also, tell your doctor or pharmacist if you are taking any of the following:
birth control medicines - drospirenone
CYP3A4 inducer medicines (such as antibiotic medicine - rifampicin, and anticonvulsant medicines - carbamazepine, phenobarbital, phenytoin)
antiarrhythmic medicines- amiodarone, quinidine
antimicrobial medicine – pentamidine
some neuroleptics
antifungal medicines - ketaconazole, itraconazole, posaconazole, voriconazole
HIV non-nucleoside reverse transcriptase inhibitor – efavirenz, etravirine
HIV protease inhibitors – atazanavir, darunavir, lopinavir, ritonavir
intravenous sedatives - benzodiazepines (e.g., alprazolam, midazolam, triazolam)
immunosuppressants – tacrolimus, sirolimus, cyclosporine
select statins - atorvastatin or pravastatin
methadone
hormonal replacement therapy - oestrogen-based medicines
medicine used to decrease blood pressure - calcium channel blockers (e.g., amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nisoldipine, verapamil)
medicine used to treat symptoms of an enlarged prostate – doxazosin and tamsulosin
warfarin and other similar medicines called vitamin K antagonists used to thin the blood. Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.
Medicinal product no longer authorised
Pregnancy must be avoided due to the use of Victrelis with ribavirin. Ribavirin can be very damaging to an unborn baby. Therefore, you and your partner must take special precautions in sexual activity if there is any chance for pregnancy to occur:
if you are a woman of childbearing age who is taking ribavirin:
you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped. You must use an effective birth control during the time you are taking ribavirin and for 4 months after stopping treatment. This should be discussed with your doctor.
if you are a man who is taking ribavirin:
do not have sex with a pregnant woman unless you use a condom. This will lessen the possibility for ribavirin to be left in the woman's body. If your female partner is not pregnant but is of childbearing age, she must be tested for pregnancy each month during treatment and for the 7 months after treatment has stopped. You or your partner must use an effective birth control during the time you are taking ribavirin and for 7 months after stopping treatment. This should be discussed with your doctor.
It is possible that boceprevir is excreted in human milk. If you are breast-feeding, your doctor will advise you to discontinue breast-feeding or to discontinue Victrelis while breast-feeding.
Reminder: Please also read the “Pregnancy and breast-feeding” section of the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Victrelis does not affect your ability to drive or use tools or machines. However, the combination therapy of Victrelis, peginterferon alfa and ribavirin may make you feel tired, faint, a sensation of your head spinning, changes in blood pressure, confused or difficulty seeing clearly. If this happens, do not drive or use any tools or machines.
Victrelis contains lactose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars (you have an intolerance to some sugars), such as Lapp lactase deficiency, or glucose-galactose malabsorption, talk to your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose of Victrelis is 4 capsules three times a day (a total of 12 capsules a day). Take the capsules in the morning, afternoon and evening with a meal or light snack. The use without food could seriously compromise your chance of success of treatment.
Peel back the tab to get to the capsule - do not push the capsule through the blister since pushing the capsule through the package may break the capsule.
Take this medicine by mouth.
This medicine should be taken with a meal or light snack.
Victrelis is always taken in combination with peginterferon alfa and ribavirin.
The duration of the administration of these medicines will depend on your response and treatment plan.
Medicinal product no longer authorised
Reminder: Please also read the “Possible side effects” in the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
If you take more Victrelis than you should, talk to a doctor or go to the nearest hospital emergency room straight away.
If you forget a dose and it is more than 2 hours before your next dose is due, take the missed dose with food. Then continue taking your capsules as normal.
However, if it is less than 2 hours before your next dose is due, skip the missed dose.
Do not take a double dose to make up for a forgotten dose. If you have any questions about what to do, talk to your doctor.
Do not stop taking Victrelis unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist because your treatment may not work.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:
difficulty breathing or swallowing, wheezing, hives, itching, swelling of your face, eyes, lips, tongue or throat – these are signs of an allergic reaction.
Medicinal product no longer authorised
thick patches of red skin – often with silvery scales
when swallowing; chest pain close to the lungs; chest pain worsens when taking a deep breath; uncontrolled salivating; overactive thyroid gland
Medicinal product no longer authorised
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreportingsystem listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blisterfoil after EXP. The expiry date refers to the last day of that month.
Storagebythepharmacist
Store in a refrigerator (2C – 8C).
Storagebythepatient
Store in a refrigerator (2C – 8C) until expiry. OR
Store outside of the refrigerator at or below 30°C for a period of not more than 3 months until expiry. After this period, the medicinal product should be disposed.
Store in the original blister in order to protect from moisture.
Medicinal product no longer authorised
Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is boceprevir. Each hard capsule contains 200 mg of boceprevir.
The other ingredients are sodium lauryl sulfate, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, pre-gelatinized starch, magnesium stearate, yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171), gelatin, and shellac.
The hard capsules have a yellowish-brown cap with the "MSD" logo printed in red ink and an off- white body with "314" printed in red ink.
Peelable blisters containing 12 hard capsules (3x4 capsule blister strip).
Pack sizes: carton of 84 hard capsules and multipack containing 336 (4 packs of 84) hard capsules. Not all pack sizes may be marketed.
Merck Sharp & Dohme Ltd S-P Labo NV
Hertford Road, Hoddesdon Industriepark 30
Hertfordshire B-2220 Heist-op-den-Berg
EN11 9BU Belgium
United Kingdom
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
MSD Belgium BVBA/SPRL
Tél/Tel: 0800 38 693 (+32(0)27766211)
UAB Merck Sharp & Dohme Tel.: +370 5 278 02 47
Мерк Шарп и Доум България ЕООД Тел.: +359 2 819 3737
Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111
MSD Pharma Hungary Kft. Tel.: +361 888 53 00
MSD Danmark ApS Tlf: +45 4482 4000
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558)
MSD SHARP & DOHME GMBH
Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)
Medicinal product no longer authorised
Merck Sharp & Dohme BV
Tel: 0800 9999000 (+31 23 5153153)
Merck Sharp & Dohme OÜ Tel.: +372 6144 200
MSD (Norge) AS Tlf: +47 32 20 73 00
msdnorge@ msd.no
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00
MSD Polska Sp.z o.o. Tel.: +48 22 549 51 00
MSD France
Tél: + 33 (0) 1 80 46 40 40
Merck Sharp & Dohme, Lda Tel: +351 21 4465700
Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 299 8700
Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: + 386 1 5204 201
Vistor hf.
Sími: +354 535 7000
Merck Sharp & Dohme, s. r. o. Tel.: +421 2 58282010
MSD Italia S.r.l.
Tel: +39 06 361911
medicalinformation.it@merck.com
MSD Finland Oy
Puh/Tel: +358 (0) 9 804650
Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700)
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272
medicalinformationuk@merck.com
Medicinal product no longer authorised